Antiviral/Antitumor Roles of Ganoderma Lucidum Spores

灵芝孢子粉的抗病毒/抗肿瘤作用

• 批准号: 6877946
• 负责人: RUI Hai LIU
• 金额: $ 15.8万
• 依托单位: CORNELL UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-04-01 至 2006-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6877946
• 关键词: Basidiomycetes; Hepadnaviridae; alternative medicine; antineoplastics; antiviral agents; biotherapeutic agent; cancer prevention; chronic disease /disorder; hepatitis B virus group; hepatocellular carcinoma; high performance liquid chromatography; liver neoplasms; marmots; neoplasm /cancer therapy; nonhuman therapy evaluation; northern blottings; southern blotting; spores; virus infection mechanism; virus replication

DESCRIPTION (provided by applicant): Over 350 million people worldwide are chronic carriers of hepatitis B virus (HBV) - over one million in the United States alone. Chronic hepatitis B infection is a major risk for the development of primary hepatocellular carcinoma (HCC). More than 500,000 people in the world die each year of HCC and most cases are associated with HBV. Interferon-a and lamivudine are the only FDA approved drugs for treatment of chronic HBV infection. There are frequent side effects and complications associated with the use of interferon-a, which also has limited efficacy with only 30% of patients responding favorably to treatment. Lamivudine is a safe drug but frequent occurrences of drug resistant mutants are observed with extended therapy. In most cases, drug withdrawal is associated with complete recrudescence of viral replication. Therefore, there is an urgent need for novel or alternative treatment methods for HBV therapy. Ganoderma lucidum spores used in Traditional Chinese Medicine (TCM) have been shown to have antiviral and anticancer activity against HBV and HCC in human patients in China. In this proposal we plan to use the woodchuck model of hepatitis B virus infection to investigate experimentally the potential of Ganoderma lucidum for prevention and treatment of HCC. The long-term goal of the project is to determine the antiviral activity Ganoderma lucidum spores against HBV and the anticancer activity of Ganoderma lucidum spores for prevention and treatment of human HCC. The specific aims are to: 1) determine the antiviral activity of Ganoderma lucidum spores against the woodchuck hepatitis virus (WHV) as a preclinical test of their potential for treatment of HBV infection and 2) determine the activity of the Ganoderma lucidum spores in the prevention and treatment of HCC in woodchucks with experimentally induced, chronic WHV infection.

描述（由申请人提供）：全世界有超过3.5亿人是B型肝炎病毒（HBV）的慢性携带者-仅在美国就超过100万。慢性B型肝炎感染是原发性肝细胞癌（HCC）发生的主要危险因素。全世界每年有超过50万人死于HCC，大多数病例与HBV有关。干扰素-a和拉米夫定是FDA批准的唯一用于治疗慢性HBV感染的药物。有频繁的副作用和并发症与使用干扰素-a，这也有有限的疗效，只有30%的患者对治疗反应良好。拉米夫定是一种安全的药物，但随着治疗时间的延长，耐药突变体的发生率也越来越高。在大多数情况下，停药与病毒复制的完全复发有关。因此，迫切需要用于HBV治疗的新的或替代的治疗方法。灵芝孢子粉用于传统中药（TCM）已被证明对中国人类患者的HBV和HCC具有抗病毒和抗癌活性。本研究拟利用B型肝炎病毒感染土拨鼠模型，探讨灵芝对肝癌的防治作用。该项目的长期目标是确定灵芝孢子对HBV的抗病毒活性和灵芝孢子预防和治疗人类HCC的抗癌活性。具体目标是：1）测定灵芝孢子对土拨鼠肝炎病毒（WHV）的抗病毒活性，作为其治疗HBV感染的潜力的临床前试验，和2）测定灵芝孢子在预防和治疗实验诱导的慢性WHV感染的土拨鼠中的HCC中的活性。